Church Kevin's Insider Trades & SAST Disclosures

Church Kevin's most recent trade in Athira Pharma Inc was a trade of 36,666 Restricted Stock Units done . Disclosure was reported to the exchange on June 30, 2025.

Stock Client Name Client Category Action Reported to Exchange Quantity Post Transaction Holding Traded % Avg. Price Value Security Type
Athira Pharma Inc
Kevin Church CHIEF SCIENTIFIC OFFICER Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 30 Jun 2025 36,666 36,667 - - Restricted Stock Units
Athira Pharma Inc
Kevin Church CHIEF SCIENTIFIC OFFICER Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 30 Jun 2025 36,666 177,427 - 0 Common Stock
Athira Pharma Inc
Kevin Church CHIEF SCIENTIFIC OFFICER Grant, award, or other acquisition of securities at price $ 0.23 per share. 30 Jun 2025 10,000 140,761 - 0.2 2,312 Common Stock
Athira Pharma Inc
Kevin Church CHIEF SCIENTIFIC OFFICER Sale of securities on an exchange or to another person at price $ 0.29 per share. 30 Jun 2025 8,526 168,901 - 0.3 2,502 Common Stock
Athira Pharma Inc
Kevin Church CHIEF SCIENTIFIC OFFICER Grant, award, or other acquisition of securities at price $ 0.00 per share. 03 Mar 2025 87,845 87,845 - - Stock Option (Right to Buy)
Athira Pharma Inc
Kevin Church CHIEF SCIENTIFIC OFFICER Grant, award, or other acquisition of securities at price $ 0.00 per share. 03 Mar 2025 58,563 58,563 - - Restricted Stock Units
Athira Pharma Inc
Kevin Church CHIEF SCIENTIFIC OFFICER Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 31 Dec 2024 36,667 139,271 - 0 Common Stock
Athira Pharma Inc
Kevin Church CHIEF SCIENTIFIC OFFICER Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 31 Dec 2024 36,667 73,333 - - Restricted Stock Units
Athira Pharma Inc
Kevin Church CHIEF SCIENTIFIC OFFICER Grant, award, or other acquisition of securities at price $ 0.55 per share. 31 Dec 2024 9,920 102,604 - 0.6 5,456 Common Stock
Athira Pharma Inc
Kevin Church CHIEF SCIENTIFIC OFFICER Sale of securities on an exchange or to another person at price $ 0.56 per share. 31 Dec 2024 8,510 130,761 - 0.6 4,782 Common Stock
Athira Pharma Inc
Kevin Church CHIEF SCIENTIFIC OFFICER Grant, award, or other acquisition of securities at price $ 0.00 per share. 01 Oct 2024 110,000 110,000 - - Stock Option (Right to Buy)
Athira Pharma Inc
Kevin Church CHIEF SCIENTIFIC OFFICER Grant, award, or other acquisition of securities at price $ 0.00 per share. 01 Oct 2024 110,000 110,000 - - Restricted Stock Units
Athira Pharma Inc
Kevin Church CHIEF SCIENTIFIC OFFICER Grant, award, or other acquisition of securities at price $ 0.00 per share. 03 Sep 2024 10,000 95,209 - 0 Common Stock
Athira Pharma Inc
Kevin Church CHIEF SCIENTIFIC OFFICER Grant, award, or other acquisition of securities at price $ 1.34 per share. 03 Sep 2024 4,953 85,209 - 1.3 6,637 Common Stock
Athira Pharma Inc
Kevin Church CHIEF SCIENTIFIC OFFICER Sale of securities on an exchange or to another person at price $ 0.57 per share. 03 Sep 2024 2,525 92,684 - 0.6 1,429 Common Stock
Athira Pharma Inc
Church Kevin CHIEF SCIENTIFIC OFFICER Grant, award, or other acquisition of securities at price $ 0.00 per share. 14 Feb 2024 220,000 220,000 - - Stock Option (Right to Buy)
Athira Pharma Inc
Kevin Church Chief Scientific Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 04 Jan 2024 10,000 82,668 - 0 Common Stock
Athira Pharma Inc
Kevin Church CHIEF SCIENTIFIC OFFICER Grant, award, or other acquisition of securities at price $ 0.00 per share. 04 Jan 2024 10,000 82,668 - 0 Common Stock
Athira Pharma Inc
Church Kevin Chief Scientific Officer Grant, award, or other acquisition of securities at price $ 1.34 per share. 04 Jan 2024 3,397 72,668 - 1.3 4,552 Common Stock
Athira Pharma Inc
Kevin Church CHIEF SCIENTIFIC OFFICER Grant, award, or other acquisition of securities at price $ 1.34 per share. 04 Jan 2024 3,397 72,668 - 1.3 4,552 Common Stock
Athira Pharma Inc
Kevin Church Chief Scientific Officer Sale of securities on an exchange or to another person at price $ 2.91 per share. 04 Jan 2024 2,412 80,256 - 2.9 7,019 Common Stock
Athira Pharma Inc
Church Kevin CHIEF SCIENTIFIC OFFICER Sale of securities on an exchange or to another person at price $ 2.91 per share. 04 Jan 2024 2,412 80,256 - 2.9 7,019 Common Stock
Athira Pharma Inc
Kevin Church Chief Scientific Officer Grant, award, or other acquisition of securities at price $ 2.41 per share. 04 Jan 2024 809 69,271 - 2.4 1,950 Common Stock
Athira Pharma Inc
Church Kevin CHIEF SCIENTIFIC OFFICER Grant, award, or other acquisition of securities at price $ 2.41 per share. 04 Jan 2024 809 69,271 - 2.4 1,950 Common Stock
Athira Pharma Inc
Kevin Church Chief Scientific Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.35 per share. 24 Mar 2023 6,410 68,462 - 1.4 8,654 Common Stock
Athira Pharma Inc
Kevin Church Chief Scientific Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 24 Mar 2023 6,410 0 - - Stock Option (Right to Buy)
Athira Pharma Inc
Kevin Church Executive VP, Research Grant, award, or other acquisition of securities at price $ 0.00 per share. 19 Jan 2023 150,000 150,000 - - Stock Option (Right to Buy)
Athira Pharma Inc
Kevin Church Executive VP, Research Grant, award, or other acquisition of securities at price $ 2.74 per share. 19 Jan 2023 657 62,052 - 2.7 1,800 Common Stock
Athira Pharma Inc
Kevin Church Executive VP, Research Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 28 Oct 2022 3,700 6,410 - - Stock Option (Right to Buy)
Athira Pharma Inc
Kevin Church Executive VP, Research Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.35 per share. 28 Oct 2022 3,700 61,395 - 1.4 4,995 Common Stock
Athira Pharma Inc
Kevin Church Executive VP, Research Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.35 per share. 08 Jun 2022 2,500 50,309 - 1.4 3,375 Common Stock
Athira Pharma Inc
Kevin Church Executive VP, Research Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 08 Jun 2022 2,500 10,110 - - Stock Option (Right to Buy)
Athira Pharma Inc
Kevin Church Executive VP, Research Grant, award, or other acquisition of securities at price $ 7.06 per share. 08 Jun 2022 243 47,809 - 7.1 1,716 Common Stock
Athira Pharma Inc
Kevin Church Executive VP, Research Grant, award, or other acquisition of securities at price $ 0.00 per share. 18 Jan 2022 100,000 100,000 - - Stock Option (Right to Buy)
Athira Pharma Inc
Kevin Church Executive VP, Research Grant, award, or other acquisition of securities at price $ 12.51 per share. 18 Jan 2022 96 44,414 - 12.5 1,201 Common Stock
Cyclerion Therapeutics Inc
Kevin Churchwell Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 24 Jun 2021 10,000 10,000 - - Stock Option (Right to Buy)
Athira Pharma Inc
Kevin Church Vice President of Discovery Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 18 May 2021 3,152 0 - - Stock Option (Right to Buy)
Athira Pharma Inc
Kevin Church Vice President of Discovery Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.04 per share. 18 May 2021 3,152 44,318 - 1.0 3,278 Common Stock
Athira Pharma Inc
Kevin Church Vice President of Discovery Grant, award, or other acquisition of securities at price $ 14.45 per share. 18 May 2021 185 41,166 - 14.4 2,673 Common Stock
Athira Pharma Inc
Kevin Church Vice President of Discovery Grant, award, or other acquisition of securities at price $ 0.00 per share. 18 Feb 2021 20,000 20,000 - - Stock Option (Right to Buy)
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc  
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges
View All The Insider Trades